Microbot Medical Osake

Microbot Medical P/CF

P/CF (Hinta-kassavirta-suhde) yhtiöstä Microbot Medical (MBOT) 3.8.2026 päivämäärällä on −13,44. Edellisenä vuonna P/CF (Hinta-kassavirta-suhde) oli −19,86 — muutos −32,34 % (korkeampi).

P/CF

−13,44

YoY

−32,34%

Viimeksi päivitetty:

P/CF (Hinta-kassavirta-suhde) yhtiöstä Microbot Medical on 2026 −13,44 . P/CF (Hinta-kassavirta-suhde) yhtiöstä Microbot Medical oli 2025 −19,86 . Se laskee −32,34% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Microbot Medical Osakeanalyysi

Mitä Microbot Medical tekee? Microbot Medical Inc. is a leading company in the development of microrobots for the medical field. The company was established in 2010 and is headquartered in Hingham, Massachusetts. Microbot Medical Inc. believes that the future of medicine lies in robotics and specializes in developing innovative solutions for complex surgical procedures and minimally invasive interventions. The company's business model is based on the development and commercialization of intelligent microrobots that will enable more precise and gentle surgical interventions. From the beginning, the company has focused on two main areas: the development of robot-assisted systems for neurosurgical procedures and the development of solutions for gastroenterology applications. In the field of neurosurgical procedures, Microbot Medical Inc. has developed the LIBERTY robot for market readiness. This robot is designed to assist surgeons during neurosurgical procedures that require increased precision and effectiveness. The robot aids the surgeon in navigating difficult-to-access areas of the brain and can help minimize the risk of tissue damage. Microbot Medical Inc. is also a leader in the development of robots in the gastroenterology field. The company has introduced the SELF-TESTER robot, which is capable of performing endoscopies in a more comfortable and painless manner. The SELF-TESTER is navigated through the digestive system and can help diagnose diseases such as cancer or inflammations in the gastrointestinal tract more effectively. Furthermore, Microbot Medical Inc. conducts research and development activities in the field of cardiovascular surgery. The company is working on a solution that allows doctors to implant aortic valves minimally invasively. The goal is to create an alternative to traditional open-heart surgery. The company has also signed a letter of intent with Cardiovascular Systems Inc. to jointly bring a new product to market that has the potential to further accelerate the minimally invasive aortic valve implantation procedure. In recent years, Microbot Medical Inc. has received several awards and recognitions, including an award from Frost & Sullivan in the category of "New Product Innovation." The company has also formed important partnerships with other leaders in the medical technology field to support the development and commercialization of its products. In conclusion, Microbot Medical Inc. is one of the leading providers of intelligent robots for the medical field and will play an important role in the development of advanced technologies that contribute to making surgical interventions more effective and safer in the coming years. The company is committed to driving innovations in medical technology and has already made a name for itself by successfully developing products in various areas. Microbot Medical on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Microbot Medical osakkeesta

Yhtiön Microbot Medical P/CF (Hinta-kassavirta-suhde) on −13,44 vuonna 2026.

P/CF (Hinta-kassavirta-suhde) yhtiöstä Microbot Medical muuttui arvosta −19,86 arvoon −13,44, mikä edustaa −32,34 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää P/CF (Hinta-kassavirta-suhde) Microbot Medical:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

Hinta-kassavirta-suhde mittaa osakekurssia suhteessa operatiiviseen kassavirtaan per osake. Toisin kuin P/E-suhde, sitä on vaikeampi manipuloida, koska kassavirta on vähemmän altis kirjanpitomuutoksille.

P/CF = Osakekurssi / Operatiivinen kassavirta per osake

Arvioidakseen P/CF (Hinta-kassavirta-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja P/CF (Hinta-kassavirta-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata P/CF (Hinta-kassavirta-suhde):n Microbot Medical alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Microbot Medical

Kaikki tunnusluvut — Microbot Medical